Personalized neoantigen DNA Vaccine (MedImmune/Washington University School of Medicine)

N/A

Report date: 2024/02/21 13:45:29

Base Information

Drug NamePersonalized neoantigen DNA Vaccine (MedImmune/Washington University School of Medicine)
Drug Alias NameN/A
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsT lymphocytes stimulants
TargetsNot applicable
Therapy Area/IndicationsHormone-Sensitive Prostate NeoplasmsSmall Cell Lung CarcinomaPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesWashington University School Of MedicineMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineAstrazeneca Plc
Inactive CompaniesMedimmune Llc
Active IndicationsHormone-Sensitive Prostate NeoplasmsSmall Cell Lung CarcinomaGlioblastoma
Inactive IndicationsPancreatic NeoplasmsTriple Negative Breast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A